CN110946957A - Traditional Chinese medicine composition for treating/preventing diabetes and application thereof - Google Patents
Traditional Chinese medicine composition for treating/preventing diabetes and application thereof Download PDFInfo
- Publication number
- CN110946957A CN110946957A CN201911412175.2A CN201911412175A CN110946957A CN 110946957 A CN110946957 A CN 110946957A CN 201911412175 A CN201911412175 A CN 201911412175A CN 110946957 A CN110946957 A CN 110946957A
- Authority
- CN
- China
- Prior art keywords
- traditional chinese
- chinese medicine
- medicine composition
- parts
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 35
- 239000003814 drug Substances 0.000 title claims abstract description 34
- 229940126680 traditional chinese medicines Drugs 0.000 claims abstract description 10
- 230000002265 prevention Effects 0.000 claims abstract description 4
- 239000009636 Huang Qi Substances 0.000 claims abstract description 3
- 241000213006 Angelica dahurica Species 0.000 claims description 7
- 241001061264 Astragalus Species 0.000 claims description 7
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 7
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 7
- 240000009022 Smilax rotundifolia Species 0.000 claims description 7
- 235000003205 Smilax rotundifolia Nutrition 0.000 claims description 7
- 235000006533 astragalus Nutrition 0.000 claims description 7
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 7
- 235000011477 liquorice Nutrition 0.000 claims description 7
- 210000004233 talus Anatomy 0.000 claims description 7
- 239000006286 aqueous extract Substances 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 7
- 235000013305 food Nutrition 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 16
- 239000008280 blood Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 230000037406 food intake Effects 0.000 description 8
- 235000012631 food intake Nutrition 0.000 description 8
- 238000005259 measurement Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Abstract
The invention relates to a traditional Chinese medicine composition with homology of medicine and food, in particular to a traditional Chinese medicine composition for treating/preventing diabetes and application thereof, wherein the traditional Chinese medicine composition for treating/preventing diabetes comprises the following traditional Chinese medicines: rhizoma Smilacis Glabrae, radix astragali, radix Angelicae sinensis, and radix Glycyrrhizae; the traditional Chinese medicine composition provided by the invention has better auxiliary prevention and treatment effects on diabetes.
Description
Technical Field
The invention relates to a traditional Chinese medicine composition with homology of medicine and food, in particular to a traditional Chinese medicine composition for treating/preventing diabetes and application thereof.
Background
Diabetes is a lifelong metabolic disease characterized by chronic hyperglycemia. Diabetes is extremely harmful, especially with high incidence of various complications. Due to long-term hyperglycemia, all systems throughout the body are affected, including the large and small blood vessels, as well as the heart, brain, kidneys, peripheral nerves, eyes, feet, and the like. According to the statistics of the world health organization, the diabetes complications are more than 100, and are the diseases with the most known complications.
Diabetes is an extremely difficult disease to treat, and the traditional therapy has unique advantages for preventing and treating diabetes and complications thereof, and proves that the traditional therapy is not only effective, but also has no adverse reaction. Has auxiliary prevention effect on the development of the complications, and can appropriately delay or relieve the complications.
Recent research discovers that a simple medicinal and edible compound recipe has obvious effect of reducing blood sugar of diabetes, is suitable for early-stage diabetes patients and/or a general traditional Chinese medicine compound recipe for preventive application of early-stage diabetes, and can also be used for auxiliary application of systemic treatment.
Disclosure of Invention
The invention provides a traditional Chinese medicine composition for treating/preventing diabetes, which has better treatment and auxiliary prevention effects on diabetes.
In order to achieve the purpose, the invention is realized by the following technical scheme:
a Chinese medicinal composition for treating/preventing diabetes comprises the following Chinese medicinal materials: rhizoma Smilacis Glabrae, radix astragali, radix Angelicae sinensis, and radix Glycyrrhizae.
Further, the traditional Chinese medicine composition consists of the following traditional Chinese medicines in parts by weight: 15-200 parts of glabrous greenbrier rhizome, 5-20 parts of astragalus, 5-20 parts of Chinese angelica and 3-30 parts of liquorice.
Further, the traditional Chinese medicine composition comprises a directly crushed product of the traditional Chinese medicine composition and a pharmaceutically acceptable carrier.
Further, the traditional Chinese medicine composition can be decoction pieces and/or extracts of the decoction pieces, including a composition of an aqueous extract and/or an alcohol extract.
The traditional Chinese medicine composition can be applied to the preparation of medicines for preventing and/or treating diabetes.
Has the advantages that:
the test result shows that the traditional Chinese medicine composition provided by the invention has no obvious influence on the weight and the food intake of the mouse. After continuous administration for 3 weeks, blood sugar of a normal blank control group (namely a G1 control group) is basically kept consistent, blood sugar of mice of an STZ-induced diabetes model control group (namely a G2 model group) is increased, the added traditional Chinese medicines have a certain blood sugar reducing effect, and the provided traditional Chinese medicine composition has the effects of assisting in preventing and treating diabetes.
Drawings
FIG. 1 is a graph showing the body weight measurements of mice in each group; (wherein the abscissa unit is: week/week)
FIG. 2 is a graph showing the measurement of food intake of mice in each group; (wherein the abscissa unit is: day/day)
FIG. 3 is a blood glucose test chart of groups of mice by Day 0;
FIG. 4 is a blood glucose test chart of groups of mice by Day 26.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are some embodiments of the present invention, but not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1:
a traditional Chinese medicine composition for treating/preventing diabetes comprises the following traditional Chinese medicines in parts by weight: 60 parts of glabrous greenbrier rhizome, 10 parts of astragalus, 10 parts of Chinese angelica and 10 parts of liquorice.
Example 2:
a traditional Chinese medicine composition for treating/preventing diabetes comprises the following traditional Chinese medicines in parts by weight: 15 parts of glabrous greenbrier rhizome, 15 parts of astragalus, 5 parts of Chinese angelica and 17 parts of liquorice.
Example 3:
a traditional Chinese medicine composition for treating/preventing diabetes is characterized by comprising the following traditional Chinese medicines in parts by weight: 160 parts of glabrous greenbrier rhizome, 5 parts of astragalus, 20 parts of Chinese angelica and 3 parts of liquorice.
Example 4:
a traditional Chinese medicine composition for treating/preventing diabetes comprises the following traditional Chinese medicines in parts by weight: 105 parts of glabrous greenbrier rhizome, 18 parts of astragalus, 17 parts of Chinese angelica and 30 parts of liquorice.
Example 5:
a traditional Chinese medicine composition for treating/preventing diabetes comprises the following traditional Chinese medicines in parts by weight: 200 parts of glabrous greenbrier rhizome, 20 parts of astragalus, 8 parts of Chinese angelica and 26 parts of liquorice.
The pharmacological performance of the traditional Chinese medicine composition is detected:
purpose of the experiment: the hypoglycemic effect of the Chinese medicinal composition of example 1 was comprehensively evaluated by using an STZ-induced diabetic model mouse as a test subject.
Experimental animals: c57BL Male mice 7-8W 72, a total of 4 groups, each group of 12.
(1) G1 control, G2 model, G3 pre-given and G4 post-given.
G1 control, a normal blank control group, i.e. mice that did not suffer from diabetes and were not induced by STZ injection; the stomach was perfused with normal saline at a dose of 10 ml/kg.
G2 model, STZ-induced diabetic mice; the stomach was perfused with normal saline at a dose of 10 ml/kg.
G3 pre-administration of Chinese medicinal materials, STZ induced diabetic mice; the aqueous extract of the Chinese medicinal composition of example 1 (the concentration of the aqueous extract of the Chinese medicinal composition is 3g/kg) was used for intragastric administration in an amount of 10 ml/kg.
G4, administering the traditional Chinese medicine to STZ-induced diabetic mice; the aqueous extract of the Chinese medicinal composition of example 1 (the concentration of the aqueous extract of the Chinese medicinal composition is 3g/kg) was used for intragastric administration in an amount of 10 ml/kg.
(2) Mice were gavaged daily for two to three weeks.
(3) The first dose of predose was 4 hours before Day1 STZ injection and the first dose of postdose was started with Day 6.
Weight of experimental part: all mice were weighed once a day;
food intake: measuring the food intake of the mice for 24h twice every two weeks and five weeks;
day-7 to Day0, 7 week old mice were acclimatized for 7 days.
Day1, STZ induced diabetes: 12 mice were fasted for 12 h. STZ was purchased from Sigma (S0130) and dissolved in pH 4.5 sodium citrate solution, ready to use and used up within 15 minutes after dissolution. IP intraperitoneal injection, STZ dose 50mg/kg, continuous injection for 5 days (4 hours fasting four days later). Day26 measures blood sugar to evaluate the model condition and drug effect.
Results of the experiment
1. Body weight
The results of the weight measurements are shown in FIG. 1.
And (4) analyzing results: body weight measurements showed that the drug had no significant effect on mouse body weight.
2. Food intake results
The results of the food intake measurements are shown in FIG. 2.
And (4) analyzing results: food intake tests show that the medicine has no obvious influence on the food intake of the mice.
3. Blood glucose results
The results of the blood glucose measurements are shown in FIG. 3.
And (4) analyzing results: comparing the blood sugar test results of Day0 and Day26, it can be seen that after continuous administration for 3 weeks, the blood sugar of the blank normal control group is basically consistent, and the blood sugar of each administration group has a different degree of descending trend compared with the blood sugar of the model control group, and has the effect of reducing blood sugar.
The above examples are only intended to illustrate the technical solution of the present invention, but not to limit it; although the present invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some technical features may be equivalently replaced; and such modifications or substitutions do not depart from the spirit and scope of the corresponding technical solutions of the embodiments of the present invention.
Claims (5)
1. A traditional Chinese medicine composition for treating/preventing diabetes is characterized by comprising the following traditional Chinese medicines: rhizoma Smilacis Glabrae, radix astragali, radix Angelicae sinensis, and radix Glycyrrhizae.
2. The traditional Chinese medicine composition for treating/preventing diabetes as claimed in claim 1, which is characterized by comprising the following traditional Chinese medicines in parts by weight: 15-200 parts of glabrous greenbrier rhizome, 5-20 parts of astragalus, 5-20 parts of Chinese angelica and 3-30 parts of liquorice.
3. The Chinese medicinal composition for treating/preventing diabetes according to claim 1 or 2, wherein the Chinese medicinal composition comprises a directly pulverized product of the Chinese medicinal composition and a pharmaceutically acceptable carrier.
4. The traditional Chinese medicine composition for treating/preventing diabetes mellitus as claimed in claim 3, wherein the traditional Chinese medicine composition can be prepared into pieces and a composition of extracts of the pieces including aqueous extracts and/or alcohol extracts.
5. Use of the Chinese medicinal composition of claim 1 or 2 in the preparation of a medicament for the prevention and/or treatment of diabetes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911412175.2A CN110946957A (en) | 2019-12-31 | 2019-12-31 | Traditional Chinese medicine composition for treating/preventing diabetes and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911412175.2A CN110946957A (en) | 2019-12-31 | 2019-12-31 | Traditional Chinese medicine composition for treating/preventing diabetes and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110946957A true CN110946957A (en) | 2020-04-03 |
Family
ID=69985211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911412175.2A Pending CN110946957A (en) | 2019-12-31 | 2019-12-31 | Traditional Chinese medicine composition for treating/preventing diabetes and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110946957A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101744869A (en) * | 2008-12-19 | 2010-06-23 | 中国科学院兰州化学物理研究所 | Compound traditional Chinese medicine extract composition for preventing and treating diabetes |
| CN109276591A (en) * | 2018-11-28 | 2019-01-29 | 吉林修正药业新药开发有限公司 | Wilsonii Radix Angelicae Sinensis Milkvetch root composition auxiliary hyperglycemic new application |
| CN112121130A (en) * | 2019-10-31 | 2020-12-25 | 福建农林大学 | Traditional Chinese medicine composition for treating/preventing type II diabetes and application thereof |
-
2019
- 2019-12-31 CN CN201911412175.2A patent/CN110946957A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101744869A (en) * | 2008-12-19 | 2010-06-23 | 中国科学院兰州化学物理研究所 | Compound traditional Chinese medicine extract composition for preventing and treating diabetes |
| CN109276591A (en) * | 2018-11-28 | 2019-01-29 | 吉林修正药业新药开发有限公司 | Wilsonii Radix Angelicae Sinensis Milkvetch root composition auxiliary hyperglycemic new application |
| CN112121130A (en) * | 2019-10-31 | 2020-12-25 | 福建农林大学 | Traditional Chinese medicine composition for treating/preventing type II diabetes and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| 周秋丽;等: "现代中药基础研究与临床", 30 June 2012, 天津科技翻译出版公司, pages: 57 * |
| 赵晓梅: "黄芪当归合剂治疗糖尿病患者的临床疗效", 中国医药指南, vol. 15, no. 09, 31 March 2017 (2017-03-31), pages 2 - 1 * |
| 龚宇;等: "当归补血汤含药血清对高糖条件下肾小球系膜细胞增殖的影响", 中西医结合研究, vol. 3, no. 04, 20 August 2011 (2011-08-20), pages 175 - 178 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hasani-Ranjbar et al. | A systematic review of the efficacy and safety of herbal medicines used in the treatment of obesity | |
| US10398747B2 (en) | Composition comprising the extract of herbal combination for preventing or treating diabetic peripheral neuropathy | |
| KR20010049156A (en) | The extract of pine needle and the use thereof | |
| JPH07196524A (en) | Crude drug composition for preventing and curing chronic alcoholism symptom and its preparation | |
| CN1069542C (en) | Medicine for treating chronic hepatism and its preparing process | |
| KR20160006812A (en) | Compositions for preventing and curing diabetes comprising extract of Paeonia lactiflora | |
| CN101953910B (en) | Coptis alkaloid and ferulic acid compound with glucose-lowering effect | |
| CN110946957A (en) | Traditional Chinese medicine composition for treating/preventing diabetes and application thereof | |
| KR20100133079A (en) | Herbal extracts composition for the prevention of alcoholic fatty liver, hyperlipidemia and hangover | |
| CN106109909A (en) | A kind of compositions for preventing and treating diabetes and hypertension | |
| US11484562B2 (en) | Composition for preventing or treating obesity comprising natural mixture extracts | |
| CN112121130A (en) | Traditional Chinese medicine composition for treating/preventing type II diabetes and application thereof | |
| KR20100111088A (en) | Composition for preventing and treating diabetes mellitus or diabetic complications comprising extract of herbal combination | |
| CN101450162A (en) | Traditional Chinese medicine composition with blood-sugar reduction function and preparation method thereof | |
| CN108186799A (en) | Ground bone slender acanthopanax dissipates and preparation method | |
| Nesari et al. | Fenugreek (Methika): Traditional Wisdom and Research Evidences | |
| Jagtap et al. | Memory Enhancing Activity of Ginger (Zingiber officinale), Its Treatments in Dementia and Alzheimers Disease | |
| KR102265793B1 (en) | Health functional food composition containing extract of Antirrhinum majus L. as an active ingredient for lowering blood glucose | |
| CN103893512B (en) | A kind of Chinese medicine composition for treating urarthritis | |
| CN110215454B (en) | Composition with effects of reducing blood sugar and blood fat and application thereof | |
| CN102133274A (en) | Chinese medicinal composition | |
| US10322158B2 (en) | Method of treatment of insulin-resistance diabetes mellitus | |
| CN106902295B (en) | Toxicity-reducing and efficacy-enhancing traditional Chinese medicine tablet for treating gout with syndrome of wind-damp-heat | |
| KR20170043484A (en) | Pharmaceutical composition for treating or improving arthritis comprising high amount of an active ingredient derived from herbal substances | |
| Devendra et al. | A REVIEW: CURRENT TRENDS OF MEDICINAL PLANTS HAVING ANTIDIABETIC ACTIVITY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |